KRON Wutah pendapatan triwulanan Kronos Bio, Inc.

Simbol lan logo merek Kronos Bio Corporation (KRON)

Quarterly revenue changes demonstrate current income trends, where -25.90 determines the latest valuation metric for Kronos Bio, Inc. (KRON). This results from management's strategy to optimize expenses and narrow the R&D portfolio. The business relies on the development of targeted drugs against tumor transcription factors under FDA supervision. The growth potential is immense: minimal production costs upon drug approval guarantee high margins.

Kronos Bio Corporation (KRON) - Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 28.06.2025

Kronos Bio (KRON) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis umum perusahaan:Kronos Bio Inc (KRON)
Barang unggulan kronosbio.com

This indicator calculates the percentage deviation of current revenue from the value of the same quarter last year, measuring business scaling rates through top-line report dynamics. The current value of -25.90 allows for an assessment of the commercial efficiency of the Kronos Bio, Inc. (KRON) innovative oncology platform, where the quarterly revenue change metric serves as a marker of market demand for the therapeutic solutions under development.

Pesaing utama

INCY - Wutah pendapatan kuartal marang kuartal|Owah-owahan pendapatan dibandhingake kuartal kepungkur HUTCHMED (HCM)|NUVB: Wutah pendapatan triwulanan|Owah-owahan pendapatan dibandhingake kuartal kepungkur Day One Bio DAWN|Wutah dodolan triwulanan MNPR|Tingkat wutah pendapatan sajrone kuartal Inhibrx Biosciences INBX|Wutah dodolan triwulanan IMAB (I-Mab Biopharma Co., Ltd.)|FENC (Fennec Pharmaceuticals Inc.) - Tambahing pendapatan triwulanan|Heron Therapeutics, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal NVCT (Nuvectis Pharma)|Coherus BioSciences, Inc. - Wutah pendapatan triwulanan|Tambahing pendapatan triwulanan CRBP (Corbus Pharma)|CRDF: Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal beyondspringpharma.com (BYSI)|Wutah pendapatan kuartal marang kuartal bioatla.com|LIXT: Tambahing pendapatan triwulanan|Wutah pendapatan triwulanan CTXR|Wutah pendapatan triwulanan Cellectar Corp (CLRB)|Wutah pendapatan kuartal marang kuartal BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Dinamika pendapatan kuartal marang kuartal|APRE: Wutah dodolan triwulanan|Tingkat wutah pendapatan sajrone kuartal Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Wutah pendapatan kuartal marang kuartal|Wutah dodolan kuartal marang kuartal NCNA|CMRX (Chimerix, Inc.) - Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Tambahing pendapatan triwulanan|Kintara - Wutah dodolan kuartal marang kuartal|Oncternal Therapeutics, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal PRTG (Portage)